Almonty Industries is entering the autumn months with a conspicuously full quiver. The tungsten producer has simultaneously extended its most critical offtake agreement, unveiled a substantial share repurchase program, and watched its flagship Korean asset transition from construction to commercial processing. Taken together, the moves paint a picture of a company that believes its moment has arrived—and is prepared to spend heavily to prove it.
The most consequential development concerns Sangdong. The mine in South Korea’s Gangwon District, long touted as the West’s answer to Chinese tungsten dominance, has begun feeding stockpiled raw material through its newly commissioned processing plant, producing saleable tungsten concentrate. That operational milestone dovetails with a significantly expanded supply contract: Almonty’s agreement with Global Tungsten & Powders, a Plansee Group entity, has been amended to stretch the offtake term for Sangdong Phase I output from 15 to 21 years. Contracted volumes climb 40 percent to 4.41 million metric ton units, while pricing terms improve by roughly 6.3 percent. At current market prices, the company projects annual contract revenue of $490 million.
The long-dated commitment addresses what has historically been the tungsten sector’s Achilles’ heel: demand certainty. With a buyer locked in for more than two decades, Almonty has effectively de-risked the revenue side of its expansion just as Sangdong approaches full capacity.
De-risking operations is just as critical on the factory floor as it is in mining contracts. Yet many employers overlook a dangerous gap in their workplace safety documentation—until an incident exposes it. A free toolkit with 41 ready-to-use checklists and templates helps you identify and document risks properly before they become costly problems. Download the free Risk Assessment Toolkit
A Quarter That Rewrote the Financial Script
The buyback announcement—approved Monday for up to 14.4 million common shares, representing about 5 percent of outstanding stock as of August 14—carries a price tag of up to $300 million. The program runs 36 months, beginning August 24 and extending to August 24, 2029. Management’s rationale, as reported by commentators, is characteristically direct: the share price does not adequately reflect the value of the company’s tungsten assets.
That confidence rests on a second-quarter performance that was, by any measure, transformative. Revenue for Q2 2026 reached C$42.989 million, up from C$7.192 million in the year-ago period—a roughly 498 percent surge. The operating result from mining swung from a C$0.9 million loss to a C$26.1 million gain, with mining gross margin hitting 60.7 percent. Net income landed at C$181.797 million, against a C$58.209 million loss a year earlier, though that figure was heavily flattered by non-cash valuation gains of approximately C$173.1 million on derivatives and warrants. Adjusted EBITDA flipped from a C$4.8 million loss to a C$17.6 million profit.
The numbers, however, still tell a story dominated by the legacy Panasqueira operation in Portugal. Sangdong was in its commissioning phase at the June 30 balance sheet date and contributed little to the quarter’s results. The European APT tungsten price, which vaulted from roughly $453 to about $3,075 per MTU, did much of the heavy lifting.
Should investors sell immediately? Or is it worth buying Almonty?
The Balance Sheet Behind the Buyback
Almonty’s capacity to fund a $300 million repurchase without jeopardizing Sangdong’s ramp-up stems from a decisively strengthened balance sheet. The company’s oversubscribed convertible bond issuance raised $800 million, leaving cash reserves of approximately C$1.23 billion as of June 30. Operating activities generated C$31.6 million of cash flow in the first half of 2026, reversing a C$14.9 million outflow in the comparable period.
That liquidity cushion also supports a parallel initiative: shelf registrations permitting the potential issuance of common shares worth roughly $246.79 million, including a component tied to employee equity participation programs.
Institutional investors appear to share management’s conviction. BlackRock added more than six million shares during the second quarter, while T. Rowe Price increased its position by approximately 10.8 million shares across two affiliated entities. On the selling side, insider Mark Trachuk disposed of roughly 200,000 shares in early July at about $16.97 per share, representing 7.4 percent of his direct holdings—a modest trim that hardly signals a loss of faith.
Streamlining the Corporate Structure
The buyback arrives amid a deliberate simplification of Almonty’s listing architecture. The voluntary delisting from the TSX is complete, and the ASX exit is scheduled for September 1, with CDI suspension and trading cessation set for August 28. Going forward, the stock will trade on the Nasdaq and in Frankfurt. An independent research note from the past Friday identified this consolidation, alongside the quarterly results and Sangdong’s progress, as the defining developments of the summer.
When you’re responsible for a workforce, regulatory compliance isn’t optional—it’s a legal duty that carries serious penalties if neglected. The Health & Safety at Work Act 1974 sets out clear obligations, yet many UK companies unknowingly fall short. A free toolkit with 9 practical tools, including risk assessments and a director’s liability guide, helps you identify where you’re exposed and fix it. Download the free Health & Safety at Work Act Toolkit
The Molybdenum side project at Sangdong is also advancing: roughly 37 percent of a planned 12,000-meter drilling program is complete, with sample grades matching historical drill results.
What emerges is a company in synchronized motion—operationally, financially, and structurally. The extended offtake agreement secures the demand side for decades; the buyback signals conviction in the equity; the balance sheet provides the means; and Sangdong’s processing plant finally delivers the proof of concept. Whether the market ultimately validates management’s view on valuation will become evident in the coming months, as the repurchase program tests actual demand for the shares.
Ad
Almonty Stock: Buy or Sell?! New Almonty Analysis from August 20 delivers the answer:
The latest Almonty figures speak for themselves: Urgent action needed for Almonty investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 20.
Almonty: Buy or sell? Read more here...
